Iron alters Ca
doxorubicin
drug resistance
intracellular calcium
iron
Journal
Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
22
11
2019
revised:
19
02
2020
accepted:
02
03
2020
pubmed:
7
3
2020
medline:
12
10
2021
entrez:
7
3
2020
Statut:
ppublish
Résumé
Iron is an essential trace element especially in cell proliferation, and growth for various cellular events. An increasing amount of research has shown that iron metabolism is altered in tumour cells which usually have rapid growth rates. However, the number of studies on iron metabolism, and calcium regulation are limited in drug-resistant tumour cells. Previously, we have shown that modulation of iron metabolism through iron chelation regulated the intracellular calcium, and increased the doxorubicin sensitivity. In the present study, we investigated the effects of iron on mRNA expression profiles of fifteen key genes (IP
Identifiants
pubmed: 32141111
doi: 10.1111/1440-1681.13295
doi:
Substances chimiques
Doxorubicin
80168379AG
Iron
E1UOL152H7
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1221-1230Informations de copyright
© 2020 John Wiley & Sons Australia, Ltd.
Références
Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007;446:749-757.
Kovalev AA, Tsvetaeva DA, Grudinskaja TV. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 2013;35:287-290.
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP dependent transporters. Nat Rev Cancer. 2002;2:48-58.
Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265-283.
Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275-292.
Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA. 1994;91:3497-3504.
Simon S, Roy D, Schindler M. Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA. 1994;91:1128-1132.
Du Y, Liu JQ, Tang J, et al. Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer. Oncotarget. 2017;8:68270-68279.
Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552-565.
Van Breemen C, Saida K. Cellular mechanisms regulating [Ca2+]i smooth muscle. Annu Rev Physiol. 1989;51:315-329.
Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signaling. Nat Rev Mol Cell Biol. 2000;1:11-21.
Sulová Z, Orlický J, Fiala R, et al. Expression of P-glycoprotein in L1210 cells is linked with rise in sensitivity to Ca2+. Biochem Biophys Res Commun. 2005;335:777-784.
Nygren P, Larsson R, Gruber A, Peterson C, Bergh J. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br J Cancer. 1991;64:1011-1018.
Padar S, van Breemen C, Thomas DW, Uchizono JA, Livesey JC, Rahimian R. Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol-resistant subclone. Br J Pharmacol. 2004;142:305-316.
Al-Taweel N, Varghese E, Florea AM, Büsselberg D. Cisplatin (CDDP) triggers cell death of MCF-7 cells following disruption of intracellular calcium ([Ca(2+)]i) homeostasis. J Toxicol Sci. 2014;39:765-774.
Pogribny IP, Tryndyak VP, Pogribna M, et al. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents. Int J Oncol. 2013;425:1822-1832.
Cazzola M, Bergamaschi G, Dezza L, Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood. 1990;75:1903-1919.
Hoffbrand AV, Ganeshaguru K, Hooton JW, Tattersall MH. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol. 1976;33:517-526.
Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13:342-355.
Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Curr Med Chem. 2003;10:1021-1034.
Yu Y, Gutierrez E, Kovacevic Z, et al. Iron Chelators for the Treatment of Cancer. Curr Med Chem. 2012;19:2689-2702.
Rao VA, Klein SR, Agama KK, et al. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase II alpha in breast cancer cells. Cancer Res. 2009;69:948-957.
Yalcintepe L, Halis E. Modulation of iron metabolism by iron chelation regulates intracellular calcium and increases sensitivity to doxorubicin. Bosn J Basic Med Sci. 2016;16:14-20.
Hoke EM, Maylock CA, Shacter E. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic Biol Med. 2005;39:403-411.
Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA. 2006;103:14901-14906.
Pinnix ZK, Miller LD, Wang W, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010;2:43-56.
Vela D. Iron Metabolism in Prostate Cancer; From Basic Science to New Therapeutic Strategies. Front Oncol. 2018;8:547.
Foskett JK, White C, Cheung KH, Mak DO. Inositol trisphosphate receptor Ca2+ release channels. Physiol Rev. 2007;87:593-658.
Kang SS, Han KS, Ku BM, et al. Caffeine-Mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res. 2010;70:1173-1183.
Sakakura C, Hagiwara A, Fukuda K, et al. Possible involvement of inositol 1,4,5-trisphosphate receptor type 3 (IP3R3) in the peritoneal dissemination of gastric cancers. Anticancer Res. 2003;23:3691-3697.
Shibao K, Fiedler MJ, Nagata J, et al. The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma. Cell Calcium. 2010;48:315-323.
Hedberg ML, Goh G, Chiosea SI, et al. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest. 2016;126:169-180.
Jayaraman T, Marks AR. T cells deficient in inositol 1,4,5-trisphosphate receptor are resistant to apoptosis. Mol Cell Biol. 1997;17:3005-3012.
Assefa Z, Bultynck G, Szlufcik K, et al. Caspase-3-induced truncation of type 1 inositoltrisphosphate receptor accelerates apoptotic cell death and induces inositol trisphosphate-independent calcium release during apoptosis. J Biol Chem. 2004;279:43227-43236.
Khan MT, Bhanumathy CD, Schug ZT, Joseph SK. Role of inositol 1,4,5-trisphosphate receptors in apoptosis in DT40 lymphocytes. J Biol Chem. 2007;282:32983-32990.
Steinmann C, Landsverk ML, Barral JM, Boehning D. Requirement of inositol 1,4,5-trisphosphate receptors for tumor-mediated lymphocyte apoptosis. J Biol Chem. 2008;283:13506-13509.
Verbert L, Lee B, Kocks SL, et al. Caspase-3-truncated type 1 inositol 1,4,5- trisphosphate receptor enhances intracellular Ca2+ leak and disturbs Ca2+ signaling. Biol Cell. 2008;100:39-49.
Marchi S, Marinello M, Bononi A, et al. Selective modulation of subtype III IP3R by Akt regulates ER Ca2 release and apoptosis. Cell Death Dis. 2012;3:e304.
Tsunoda T, Koga H, Yokomizo A, et al. Inositol 1,4,5-trisphosphate (IP3) receptor type 1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene. 2005;24:1396-1402.
Vervloessem T, Yule DI, Bultynck G, Parys JB. The type 2 inositol 1,4,5-trisphosphate receptor, emerging functions for an intriguing Ca2-release channel. Biochim Biophys Acta. 2015;1853:1992-2005.
Pelzl L, Hosseinzadeh Z, Alzoubi K, et al. Impact of Na+/Ca2+ exchangers on therapy resistance of ovary carcinoma cells. Cell Physiol Biochem. 2015;37:1857-1868.
Pelzl L, Hosseinzadeh Z, Al-Maghout T, et al. Role of Na+/Ca2+ exchangers in therapy resistance of medulloblastoma cells. Cell Physiol Biochem. 2017;42:1240-1251.
Tenopoulou M, Kurz T, Doulias PT, Galaris D, Brunk UT. Does the calcein-AM method assay the total cellular 'labile iron pool' or only a fraction of it? Biochem J. 2007;403:261-266.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101-1108.
Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440-3450.